Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840888 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3484356 in Healthy Female Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT04840888 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 82 participants.
The verdict
NCT04840888, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and safety of LY3484356 by collecting the information about any side effects that may occur. The participant's involvement with the study will last approximately 27 days, not including screening.
Interventions
- DRUG Midazolam
- DRUG Itraconazole
- DRUG Omeprazole
- DRUG Carbamazepine
- DRUG LY3484356
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04840888
The ClinicalTrials.gov registry entry for NCT04840888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT04840888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04840888 about?
NCT04840888 is a clinical study titled "A Study of LY3484356 in Healthy Female Participants". The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and saf...
What is the current status of trial NCT04840888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2021-04-26. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT04840888?
The interventions under investigation include: Midazolam (DRUG), Itraconazole (DRUG), Omeprazole (DRUG), Carbamazepine (DRUG), LY3484356 (DRUG).
Who is sponsoring clinical trial NCT04840888?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.